What’s on Sanofi’s M&A list now that Medi­va­tion is gone? Cat­a­lyst gets an SPA; Adap­ti­m­mune part­ners with Mer­ck

As we’ve said be­fore at End­points News, this has been a rough year for Sanofi $SNY. Now that Medi­va­tion has slipped through its fin­gers, falling to Pfiz­er, CEO Olivi­er Brandi­court has had to an­swer fresh ques­tions about its M&A strat­e­gy. What will be their next tar­get? The an­swer — in their Q3 call — was can­cer, im­munol­o­gy and rare dis­eases. Says the CEO: “When it comes to what is go­ing to be our in­ter­est in the fu­ture, on­col­o­gy is still part of it, if we are find­ing po­ten­tial tar­gets which make sense strate­gi­cal­ly and eco­nom­i­cal­ly. But we are open­ing our M&A strat­e­gy to what we said last year, which is a seg­ment where we con­sid­er that we have es­tab­lished, al­ready, some good pres­ence, but we need to strength­en that pres­ence by in­or­gan­ic growth. And so, we men­tioned sev­er­al things last year. We men­tioned im­munol­o­gy, we men­tioned MS. Even in the first mar­ket, if you think about it, we are in ge­net­ic rare dis­eases, so rare dis­ease can be al­so an area.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER